Mohd Ashhad: The Science Behind a Safe Transfusion
Mohd Ashhad, Medical Laboratory Technologist at Blood Bank, shared a post on LinkedIn։
”A Routine Crossmatch, But Never Just a Routine Job
Today in the blood bank, I worked on an interesting transfusion case.
The patient’s blood group was AB Positive, and an AB Negative red cell unit was selected for transfusion. Although the ABO groups were compatible, we still needed to confirm that the selected donor unit was serologically compatible with the patient.
That’s where crossmatching becomes important.
Crossmatch performed:
Gel Card / Column Agglutination Technique – AHG phase
The patient’s plasma was tested against the donor red cells. After the required incubation and centrifugation steps, the reaction pattern in the gel column was carefully observed.
Result: Compatible
There was no significant agglutination observed, with the red cells forming a compact cell button at the bottom of the microtube.
Why is crossmatching important?
Blood grouping tells us the patient’s ABO and Rh(D) type, but it doesn’t tell the complete story. A patient may have clinically significant antibodies against red-cell antigens that are not detected simply by ABO/Rh typing.
Crossmatching helps us check whether the specific donor red cells selected for that patient are compatible before transfusion.
For me, this is one of the most important parts of blood bank work. A small gel card may look simple, but behind every result there is careful testing, observation, documentation, and responsibility.
Every compatible unit is more than a laboratory result—it is one step toward a safe transfusion.”

Stay updated with Hemostasis Today.
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator
-
Aug 24, 2026, 15:15Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?